Synergistic value of systemic inflammatory and tumor markers in predicting pretreatment distant metastasis of gastric cancer

Table 2 Comparison of gastric cancer patients between metastatic and non-metastatic groups in the training set, n (%)/median (interquartile range)

Characteristic	Non-metastatic group (n = 94)	Metastatic group (n = 58)	P value
Sex			0.914
Male	64 (68.1)	39 (67.2)
Female	30 (31.9)	19 (32.8)
Age			0.426
< 60 years	44 (46.8)	27 (46.6)
≥ 60 years	50 (53.2)	31 (53.4)
Tumor location			< 0.001
Cardia	22 (23.4)	29 (50.0)
Antrum	59 (62.8)	19 (32.8)
Body	13 (13.8)	10 (17.2)
CEA	2.25 (1.56, 3.98)	7.42 (1.92, 79.93)	< 0.001
CA19-9	11.31 (6.04, 18.19)	57.45 (7.91, 175.68)	< 0.001
NE	2.91 (2.38, 3.79)	4.06 (2.84, 6.83)	< 0.001
LY	1.50 (1.20, 1.90)	1.20 (0.90, 1.50)	< 0.001
MON	0.36 (0.29, 0.44)	0.41 (0.32, 0.50)	0.105
PLT	220.50 (187.50, 270.50)	223.50 (181.25, 300.50)	0.799
NLR	1.95 (1.33, 2.76)	3.57 (2.77, 5.55)	< 0.001
LMR	4.44 (3.07, 6.15)	2.86 (2.30, 3.85)	< 0.001
PLR	150.24 (105.08, 212.00)	186.00 (130.61, 302.65)	0.002
SII	439.54 (298.28, 681.39)	906.07 (505.75, 1785.25)	< 0.001
SIRI	0.76 (0.43, 0.76)	1.48 (0.84, 2.94)	< 0.001

Calculation methods: Neutrophil-to-lymphocyte ratio = neutrophils/Lymphocytes; lymphocyte-to-monocyte ratio = lymphocytes/monocytes; platelet-to-lymphocyte ratio = platelets/Lymphocytes; systemic immune-inflammation index = (neutrophils × platelets)/Lymphocytes; systemic inflammation response index = (neutrophils × monocytes)/Lymphocytes. CEA: Carcinoembryonic antigen; CA19-9: Carbohydrate antigen 19-9; NE: Neutrophils; LY: Lymphocytes; MON: Monocytes; PLT: Platelets; NLR: Neutrophil-to-lymphocyte ratio; LMR: Lymphocyte-to-monocyte ratio; PLR: Platelet-to-lymphocyte ratio; SII: Systemic immune-inflammation index; SIRI: Systemic inflammation response index.